We are pleased to present our latest analyses, showing that multiple immunofluorescence (MIF) can be used in large multicenter clinical trials to define the prognostic/predictive value of programmed death-ligand 1 (PD-L1) by concomitantly and precisely assessing its expression and spatial distribution in the tumour tissue, outperforming classical immunohistochemistry (IHC).
Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study
Canzonieri, VincenzoCo-primo
Writing – Review & Editing
;
2025-01-01
Abstract
We are pleased to present our latest analyses, showing that multiple immunofluorescence (MIF) can be used in large multicenter clinical trials to define the prognostic/predictive value of programmed death-ligand 1 (PD-L1) by concomitantly and precisely assessing its expression and spatial distribution in the tumour tissue, outperforming classical immunohistochemistry (IHC).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Programmed death-ligand 1 expression and prognostic.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
2.97 MB
Formato
Adobe PDF
|
2.97 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
